In the larger dataset of metastatic tumor tissue from patients with ERBB2 non-amplified breast cancer, however, this finding was statistically significant [22 of 405 samples (5.4%) vs 15 of 115 samples (13.0%), p = 0.0119] (Fig. 3D). Here, ERBB2 is linked to breast carcinoma.